Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

50.78 -1.15 (-2.21%)

Streaming Delayed Price Updated: 12:30 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

35 36 Next >

Why Atea Pharmaceuticals Stock Is Sinking Today ↗

November 17, 2021

Roche calls it quits on the duo's attempt to develop an oral COVID-19 therapy.

Via The Motley Fool

Atea Shares Plunge As Roche Culls Partnership To Develop COVID-19 Pill ↗

November 17, 2021

Roche Holdings AG (OTC: RHHBY) has ended a partnership with Atea Pharmaceuticals Inc (NASDAQ: AVIR) to jointly develop a COVID-19 antiviral pill, a month...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

November 17, 2021

Good morning, trader! We're halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

Atea Pharma Stock Collapses As Roche Pulls The Plug On Pfizer-Rivaling Covid Pill ↗

November 16, 2021

Roche and Atea's partnership will end in February.

Via Investor's Business Daily

Tuesday Market Overview ↗

November 16, 2021

While gold gained modestly again today, cryptocurrencies fell hard.

Via Talk Markets

Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up ↗

November 12, 2021

Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products.

Via Talk Markets

Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail ↗

November 12, 2021

The European Commission (EC) has approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and...

Via Benzinga

Johnson & Johnson Pops As It Announces The Biggest Split In Health Care ↗

November 12, 2021

Johnson & Johnson will split its consumer health unit into a publicly traded company.

Via Investor's Business Daily

The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares ↗

November 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...

Via Benzinga

Veteran's Day ↗

November 11, 2021

Stock markets took a tumble today across the board, but not as far down as at the opening.

Via Talk Markets

EU Regulator Backs Regeneron-Roche's COVID-19 Drug ↗

November 11, 2021

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc...

Via Benzinga

Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters ↗

November 10, 2021

With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition....

Via Benzinga

ALX Oncology Falls After Updated Data For Solid Tumors Candidate ↗

November 09, 2021

ALX Oncology Holdings Inc (NASDAQ: ALXO) released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. One cohort included gastric/...

Via Benzinga

These OTCQX & OTCQB Securities Had the Most Trading Activity in October ↗

November 09, 2021

Photo by Burak Kebapci from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose ↗

November 08, 2021

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has announced additional results from a Phase 3 trial, which assessed a single dose of REGEN-COV (1,200 mg...

Via Benzinga

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

The Old Lady Of Threadneedle Street ↗

November 05, 2021

US markets are up on better jobs growth reported for October today.

Via Talk Markets

Will Pfizer Outgun Merck With Oral COVID-19 Pill? ↗

November 05, 2021

Merck, Inc. (NYSE: MRK) is locking horns with peer Pfizer, Inc. (NYSE: PFE) in what could be termed as the battle supremacy in the COVID-19 treatment market. The stakes are high,...

Via Benzinga

Thursday Market Overview ↗

November 04, 2021

If you are an IBM shareholder you now own something new Kyndryl.

Via Talk Markets

7 European Stocks to Buy to Diversify Your Portfolio ↗

November 04, 2021

While exposure to U.S.-based securities continues to be a good idea, you can diversify your opportunities by considering European stocks.

Via InvestorPlace

Novartis To Offload Its Stake Back To Roche For $20.7B ↗

November 04, 2021

Novartis AG (NYSE: NVS), a shareholder in Roche Holdings AG (OTC: RHHBY) for more than 20 years, would sell its entire stake, which is nearly one-third voting...

Via Benzinga

Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting ↗

November 02, 2021

Galecto Inc (NASDAQ: GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC: RHHBY) to explore the combination of GB1211 in...

Via Benzinga

Cyber Currency ↗

October 26, 2021

Canadian stocks are particularly buoyant and not just in energy which is a riser today because the loony is up against the buck.

Via Talk Markets

Default Avoided ↗

October 22, 2021

The Chinese real estate firm Evergrande managed to pay the interest it owes to foreign bondholders.

Via Talk Markets

Why Atea Pharmaceuticals Stock Got Crushed This Week ↗

October 22, 2021

A mid-stage trial miss caused investors to hit the exits this week.

Via The Motley Fool

FDA Approves Genentech’s Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD)

October 22, 2021

From Genentech

Via Business Wire

The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs ↗

October 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas...

Via Benzinga

Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market ↗

October 21, 2021

Cortexyme is testing a twice-day pill to treat Alzheimer's disease.

Via Investor's Business Daily

Wednesday Market Coverage ↗

October 20, 2021

Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal.

Via Talk Markets

Roche Expects Higher FY21 Sales As Delta Variant Boosts Demand For Diagnostics ↗

October 20, 2021

Roche Holding AG (OTC: RHHBY) raised its 2021 sales forecast after posting an 8% rise in nine-month revenues, driven by demand for COVID-19 tests and the strong...

Via Benzinga

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.